Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000539433 | SCV000626466 | benign | Fanconi anemia | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000987093 | SCV001136291 | likely benign | Fanconi anemia complementation group A | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001144633 | SCV001305246 | uncertain significance | Fanconi anemia complementation group D2 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Ce |
RCV001531560 | SCV001746754 | uncertain significance | not provided | 2021-06-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001531560 | SCV002098210 | uncertain significance | not provided | 2022-01-03 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Sema4, |
RCV000539433 | SCV002529473 | likely benign | Fanconi anemia | 2021-06-19 | criteria provided, single submitter | curation | |
Prevention |
RCV003942731 | SCV004761736 | likely benign | FANCD2-related disorder | 2023-08-04 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Genetic Services Laboratory, |
RCV003151085 | SCV003839514 | uncertain significance | not specified | 2022-06-01 | no assertion criteria provided | clinical testing | DNA sequence analysis of the FANCD2 gene demonstrated a sequence change, c.182C>T, in exon 3 that results in an amino acid change, p.Thr61Met. This sequence change does not appear to have been previously described in individuals with FANCD2-related disorders. This sequence change has been described in the gnomAD database with a frequency of 0.4% in the Ashkenazi Jewish subpopulation (dbSNP rs35110529). The p.Thr61Met change affects a poorly conserved amino acid residue located in a domain of the FANCD2 protein that is not known to be functional. The p.Thr61Met substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Thr61Met change remains unknown at this time. |